10-K: Viatris Reports $3.5 Billion Net Loss Amid Restructuring

Viatris Inc. reported a significant net loss of $3.51 billion for 2025, driven by a $2.94 billion goodwill impairment and declining revenues, despite advancing its strategic portfolio and pipeline.

Summary

• Viatris reported total revenues of $14.30 billion for 2025, a 3% decrease from $14.74 billion in 2024.
• The company incurred a net loss of $3.51 billion, or $3.00 diluted loss per share, for 2025, compared to a net loss of $634.2 million, or $0.53 diluted loss per share, in 2024.
• A significant non-cash goodwill impairment charge of $2.94 billion was recorded in the first quarter of 2025, primarily due to increased business risks and uncertainty in geopolitical and economic environments.
• Gross profit decreased to $5.01 billion (35% gross margin) in 2025 from $5.62 billion (38% gross margin) in 2024.
• The company initiated an Enterprise-Wide Strategic Review (EWSR) in 2025, leading to planned restructuring activities including a global workforce reduction of up to 10% and expected pre-tax charges of $700 million to $850 million.
• Viatris completed several divestitures in 2023-2024, including its women's healthcare, API, and OTC businesses, and entered into definitive agreements in December 2025 to sell its equity stake in Biocon Biologics for $815.0 million.
• Pipeline progress included five positive Phase 3 data readouts for various innovative treatments and new product launches such as Inpefa in the UAE and Iron Sucrose Injection in the U.S.
• The company returned over $1 billion to shareholders in 2025, comprising $500.5 million in share repurchases and $561.2 million in dividends.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative filing due to the substantial net loss, significant goodwill impairment, and declining revenues, despite ongoing strategic restructuring and pipeline advancements. Operational challenges and litigation risks further weigh on the sentiment.

Positives

• Achieved strong commercial execution with $14.30 billion in total revenues, demonstrating renewed momentum in the base business despite divestiture impacts and the Indore facility issues.
• Advanced its innovative pipeline with five positive Phase 3 data readouts, including for EFFEXOR in Japan, meloxicam for acute pain, a low-dose estrogen weekly dermal patch, and ophthalmic solutions for night driving impairment and presbyopia.
• Successfully launched new products such as Inpefa (sotagliflozin) in the United Arab Emirates and Iron Sucrose Injection, USP, in the U.S.
• Returned over $1 billion of capital to shareholders in 2025, including approximately $500.5 million in share repurchases and $561.2 million in dividends.
• Made substantial progress on initial remediation activities at the oral finished dose manufacturing facility in Indore, India, and is in regular communication with the FDA.
• Acquired Aculys Pharma in October 2025, expanding its portfolio of innovative neurological treatments in Japan with pitolisant and Spydia Nasal Spray.

Negatives

• Reported a significant net loss of $3.51 billion in 2025, a substantial increase from the $634.2 million net loss in 2024.
• Experienced a 3% decrease in total revenues to $14.30 billion in 2025, partly due to the impact of divestitures and the Indore facility issues.
• Recorded a $2.94 billion non-cash goodwill impairment charge in Q1 2025, reflecting increased business risks and market volatility.
• Gross margin declined to 35% in 2025 from 38% in 2024, with adjusted gross margin also decreasing to 56% from 58%.
• The FDA issued a warning letter and import alert for the Indore, India manufacturing facility in 2024, restricting 11 products from the U.S. market and negatively impacting 2025 revenues by approximately $370 million.
• A fire occurred at the Nashik, India oral solid dose manufacturing facility in February 2026, temporarily suspending operations with an expected resumption in April 2026, posing a risk to financial position if insurance is inadequate.
• Incurred higher R&D expenses of $965.9 million in 2025, an increase of $157.2 million, primarily due to the selatogrel and cenerimod development programs.
• Recognized a $534.8 million loss in 2025 from changes in the fair value of Compulsory Convertible Preferred Shares (CCPS) in Biocon Biologics.

Risks

• Failure to realize intended benefits or achieve goals from strategic initiatives, including the enterprise-wide strategic review, divestitures, acquisitions, or other potential transactions.
• Restructuring activities may not achieve intended cost savings, could cause operational interruptions, difficulty retaining employees, or higher-than-anticipated costs.
• Risks and uncertainties associated with divestitures, product rationalizations, and asset sales, including asset impairments and continued financial/operational exposure to divested assets.
• Challenges in integrating acquired businesses, potentially leading to diversion of management attention, loss of institutional knowledge, or failure to achieve anticipated synergies.
• Imposition of tariffs, trade restrictions, or domestic sourcing requirements could increase costs, disrupt supply chains, and reduce profit margins.
• Continued pressure on product pricing and reimbursements due to government controls, social pressure, and consolidation across the supply chain, including impacts from China's Volume-Based Procurement (VBP) policy and the U.S. Inflation Reduction Act.
• Risks inherent in conducting global business, such as compliance with diverse laws, political instability, conflicts (e.g., Russia-Ukraine, Middle East), inflation, and currency fluctuations.
• Charges to earnings resulting from acquisitions, including potential impairment of goodwill or intangible assets, which significantly impacted 2025 results.
• Illegal distribution and sale of counterfeit or IP-infringing products, or diverted/stolen products, could harm reputation and business.
• Vigorous competition from other pharmaceutical manufacturers, including lower-cost generics and biosimilars, threatening commercial acceptance and pricing of products.
• Dependence on a limited number of manufacturing facilities and third-party suppliers, increasing vulnerability to disruptions, quality issues, and supply shortages.
• Inability to attract, motivate, and retain key personnel, especially during periods of strategic change and restructuring.
• Exposure to anti-corruption laws (FCPA, UK Bribery Act, Chinese anti-corruption laws) with potential for substantial fines and penalties.
• Allegations of intellectual property infringement by competitors, leading to costly litigation, delays in product launches, or substantial monetary damages.
• Failure to successfully introduce new products in a timely manner due to inherent R&D risks, regulatory approval delays, or lack of market acceptance.
• Increasing dependence on IT and information systems, with risks of cybersecurity threats, data leakage, and operational disruptions.
• Legal and regulatory risks, reputational harm, or other adverse consequences from incorporating Machine Learning (ML), Artificial Intelligence (AI), and other emerging technologies.
• Increasing scrutiny and evolving expectations regarding Environmental, Social, and Governance (ESG) practices, potentially imposing additional costs or risks.
• Risks related to climate change, including extreme weather, natural disasters, and regulations to limit greenhouse gas emissions or water usage.
• Significant indebtedness could limit financial flexibility, increase vulnerability to economic conditions, and lead to higher interest rates upon refinancing.
• Inherent uncertainties in estimates, judgments, and assumptions used in financial statements, potentially leading to restatements or revisions.
• Volatility in the market price of common stock due to various factors, including operating performance, analyst recommendations, and litigation.

Future Outlook

Viatris is focused on three strategic imperatives: driving its base business through successful launches and portfolio evolution towards higher-margin products, fueling its innovative portfolio with late-stage and in-market growth assets, and modernizing for sustainable growth by strengthening technology, data, and talent capabilities. The company anticipates completing restructuring activities, including a global workforce reduction of up to 10%, primarily over the next three years, expecting $600 million to $700 million in savings. Regulatory actions are anticipated for the low dose estrogen weekly dermal patch by July 30, 2026, and for MR-141 in the second half of 2026. The Indore facility is expected to be ready for FDA reinspection in 2026, and operations at the Nashik facility are expected to resume in April 2026.

Management Comments

• Executive management is focused on ensuring the Company is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers and other key stakeholders.
• Viatris's ability to sustainably deliver high-quality medicines is grounded in its mission to empower people worldwide to live healthier at every stage of life.
• The Company is committed to advancing sustainable operations and innovative solutions to improve patient health and support more resilient healthcare systems.
• Viatris believes its global leadership in all these areas uniquely positions the Company to efficiently and effectively serve patients regardless of geography or circumstance.
• The Company is enhancing its capital allocation approach to business development, and its organic and inorganic R&D investments through a focused governance structure to ensure the highest level of strategic decision-making.
• Viatris takes very seriously its continued and comprehensive oversight of its entire manufacturing network. Patient safety remains our primary and unwavering focus. We will work closely with our customers to mitigate any possible supply disruptions and meet the needs of the patients we serve.

Industry Context

StockSavvy.ai notes that Viatris operates in a highly competitive and regulated global pharmaceutical industry, characterized by significant pricing pressures from governments and payors, increasing generic competition, and the need for continuous innovation. The company's strategic shift towards more complex and innovative, patent-protected assets aligns with a broader industry trend to seek higher-margin products amidst the erosion of exclusivity for established brands. The ongoing challenges with manufacturing facilities (Indore, Nashik) highlight the critical importance of supply chain resilience and regulatory compliance in the pharmaceutical sector. The company's divestitures and restructuring efforts reflect a common industry strategy to streamline operations and focus on core competencies to drive sustainable growth.

Comparison to Industry Standards

• Viatris's reported net loss of $3.51 billion and declining revenues contrast with the general growth trends seen in some segments of the pharmaceutical industry, particularly in innovative and specialty pharmaceuticals. While the filing does not provide direct comparisons, the significant goodwill impairment suggests a re-evaluation of asset values that may be more pronounced than some peers who have maintained stronger market valuations.
• The company's focus on expanding its innovative portfolio with late-stage and in-market growth assets, such as selatogrel and cenerimod, aligns with strategies of major pharmaceutical companies like Pfizer and Novartis, which continuously invest in R&D for new, patent-protected therapies to offset generic erosion.
• The challenges faced with the Indore manufacturing facility and the Nashik fire underscore the operational risks inherent in global pharmaceutical manufacturing, a concern shared across the industry, as evidenced by similar regulatory actions against other large generic manufacturers like Teva and Sandoz in the past.
• Viatris's capital return strategy, including over $1 billion in share repurchases and dividends in 2025, is a common practice among mature pharmaceutical companies, such as Johnson & Johnson or Merck, to enhance shareholder value, although the sustainability of such returns is scrutinized given the current financial performance.

Corporate Governance

Legal Proceedings

• EpiPen Auto-Injector Litigation: Settled a direct purchaser class action for $73.5 million in December 2024. Resolved a case with Rochester Drug Company, Dakota Drug, and Morris & Dickson Company. Resolved a complaint filed by the State of Indiana. Received a civil subpoena from the Attorney General of Mississippi, with settlements and settlements-in-principle reached with certain State Attorneys General. Total accrual of approximately $48.8 million related to these matters at December 31, 2025.
• Drug Pricing Civil Litigation: Named as a defendant in numerous lawsuits alleging anticompetitive conduct with respect to generic drugs, consolidated in an MDL in the EDPA. Bellwether cases for Clomipramine and Clobetasol are stayed pending class certification appeals. Three non-class bellwether trials are scheduled for September 2026, August 2027, and January 2028. Federal Court in Canada denied Plaintiffs' motion for class certification in February 2026.
• Attorneys General Litigation: Named in complaints by various state attorneys general alleging anticompetitive conduct with respect to generic drugs, seeking monetary damages, civil penalties, and injunctive relief. Some claims for disgorgement and restitution under federal law and certain state law claims have been dismissed.
• Securities Related Litigation: Abu Dhabi Investment Authority (ADIA) filed a complaint alleging false or misleading statements regarding EpiPen and generic drugs; an agreement-in-principle to resolve this matter has been reached. A putative class action (WDPA Mylan N.V. Class Action Litigation) alleging false statements regarding manufacturing plants was settled for $60 million in February 2026, subject to court approval. Skandia Litigation, with similar allegations, has been resolved. WDPA Viatris Class Action Litigation regarding projected financial performance and biosimilars was dismissed, and the appeal rejected. WDPA Indore Class Action Litigation and a related stockholder derivative action were filed in 2025, alleging false statements regarding the Indore manufacturing facility.
• Opioids: Reached a nationwide settlement framework in April 2025 to resolve opioid-related claims by States, local governments, and Native American tribes for up to $335 million over nine years. Certain cases not covered by the settlement remain pending. Accrued approximately $335 million for these matters at December 31, 2025.
• Citalopram: Involved in a case in the U.K. Competition Appeals Tribunal seeking monetary damages related to alleged EU competition rule violations. Accrued approximately 12.0 million as of December 31, 2025.
• Perindopril: European Commission decision upheld in June 2024 regarding EU competition rule violations. Named as a defendant in damages actions in the English High Court and Amsterdam District Court.
• Product Liability: Involved in lawsuits related to alleged personal injuries from certain products. Accrued approximately $67.1 million at December 31, 2025.
• Nitrosamines: Parties to litigation relating to alleged trace amounts of nitrosamine impurities in valsartan and ranitidine. Reached an agreement in principle to resolve valsartan personal injury lawsuits in the U.S. Trial court dismissed remaining claims against generic defendants for ranitidine.
• Lipitor: Named in lawsuits alleging type 2 diabetes from Lipitor ingestion. Federal cases dismissed, state court proceedings pending in Missouri and New York.
• Depo-Provera: Named in lawsuits alleging meningiomas from Depo-Provera. Dismissed without prejudice from all cases in the MDL. Seeking indemnification from Pfizer.
• Dimethyl Fumarate (DMF): Challenged the European Commission's revocation of generic DMF marketing authorizations; challenge denied in February 2026, with an appeal intended. Biogen filed damages actions in European commercial courts. Viatris has resumed commercializing DMF in Europe.
• Yupelri: Facing patent infringement actions from generic companies. Settlement agreements reached with most filers, granting licenses in April 2039 or earlier. One ANDA filer remains in litigation.
• Tyrvaya: Facing patent infringement actions from generic companies. Settlement agreement reached with one filer, granting licenses in October 2034 or earlier. A second generic filer initiated litigation in January 2026, resulting in an automatic stay of FDA approval until June 2028.
• Ryzumvi: Facing a patent infringement action from a generic company, resulting in an automatic stay of FDA approval until August 3, 2027.
• Other Litigation: Approximately $9.1 million accrued for various other commercial, contractual, employment, or similar matters at December 31, 2025.

Related Party Transactions

• In December 2025, Viatris entered into definitive agreements with Biocon for the sale of its equity stake (CCPS) in Biocon Biologics for $815.0 million, consisting of $400.0 million in cash and $415.0 million in newly issued equity shares of Biocon. This transaction closed in Q1 2026.
• Viatris has generally assumed liability for, and control of, pending and threatened legal matters relating to the Upjohn Business and has agreed to indemnify Pfizer for liabilities arising out of such assumed legal matters, as per the Combination agreement.
• Viatris agreed to pay Pfizer an amount equal to 57% of any losses incurred from third-party actions related to the manufacture, distribution, marketing, promotion, or sale of opioid products by or on behalf of Viatris, its predecessors, or subsidiaries since July 29, 2019.

Stakeholder Impact

• Shareholders: Experienced a significant net loss and goodwill impairment, potentially impacting investment value. However, the company continued quarterly dividends and share repurchases, aiming to return capital.
• Employees: A global workforce reduction of up to 10% is expected as part of the EWSR, leading to job losses and potential morale impacts. Management is focused on attracting, motivating, and retaining key personnel amidst these changes.
• Customers: Supply disruptions from the Indore facility issues and the Nashik fire could affect product availability. The company is working to mitigate these disruptions and maintain supply reliability.
• Suppliers: The divestiture of the API business and subsequent manufacturing and supply agreements create dependence on the API business buyer, potentially affecting supply chain stability and pricing.
• Creditors: Significant indebtedness and a decline in financial performance could increase vulnerability to adverse economic conditions and potentially impact the company's ability to meet debt obligations, although Viatris reports compliance with debt covenants.

Next Steps

• Complete restructuring activities from the Enterprise-Wide Strategic Review (EWSR) over the next three years, including a global workforce reduction of up to 10%.
• Prepare the Indore, India manufacturing facility for FDA reinspection in 2026 to resolve the warning letter and import alert.
• Resume manufacturing operations at the Nashik, India facility in April 2026 following the fire.
• Await FDA target action date of July 30, 2026, for the low dose estrogen weekly dermal patch.
• Anticipate FDA action during the second half of 2026 for MR-141 (phentolamine ophthalmic solution 0.75%) for presbyopia.
• Continue advancing the innovative pipeline, including selatogrel and cenerimod clinical trials.
• Appeal the General Court of the European Union's decision regarding generic Dimethyl Fumarate marketing authorizations to the CJEU.
• Continue to defend against remaining legal proceedings, including drug pricing and product liability lawsuits.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' for Viatris. While the company faces significant headwinds, including a substantial net loss, goodwill impairment, and declining revenues, it is actively engaged in a comprehensive restructuring and portfolio optimization strategy. The divestitures aim to streamline the business, and investments in innovative pipeline assets offer long-term growth potential. However, the immediate financial performance is weak, and operational challenges at manufacturing facilities, coupled with extensive litigation risks, create considerable uncertainty. A seasoned investor would likely monitor the execution of the EWSR, the resolution of regulatory issues, and the progress of the innovative pipeline before considering a more aggressive stance, balancing the current risks against the potential for future value creation from the strategic transformation.

Keywords

Pharmaceuticals, Generics, Branded Medicines, Biosimilars, Global Healthcare, SEC Filing, 10-K, Financial Results, Net Loss, Goodwill Impairment, Restructuring, Divestitures, Pipeline, R&D, Manufacturing, Regulatory Compliance, Drug Pricing, Litigation, Share Repurchase, Dividends, Viatris